Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-800-4 | CAS number: 88-12-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Data derived over an extensive series of robust guideline-equivalent experiments and presented in peer-reviewed journals and at professional conferences.
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Disposition and metabolism of N-Vinyl Pyrrolidone in the Rat
- Author:
- McClanahan, J. et al
- Year:
- 1 987
- Bibliographic source:
- Proceedings of the 2nd International Symposium of Povidone, University of Kentucky, School of Pharmacology, April12-15, 1987. pp. 318-329
- Reference Type:
- publication
- Title:
- Disposition of N-Vinyl 2-Pyrrolidone in the Rat
- Author:
- McClanahan, J. et al.
- Year:
- 1 983
- Bibliographic source:
- Drug Chem. Toxicol. 7(2), 129-148
- Reference Type:
- publication
- Title:
- Abstract no. 580, N-Vinyl 2-Pyrrolidone: Disposition and Metabolism Studies
- Author:
- Digenis, G.A, et. al.
- Year:
- 1 982
- Bibliographic source:
- The Toxicologist 2(1), 165
Materials and methods
- Objective of study:
- distribution
- excretion
- metabolism
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: no data
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 1-vinyl-2-pyrrolidone
- EC Number:
- 201-800-4
- EC Name:
- 1-vinyl-2-pyrrolidone
- Cas Number:
- 88-12-0
- Molecular formula:
- C6H9NO
- IUPAC Name:
- 1-ethenylpyrrolidin-2-one
- Details on test material:
- - Name of test material (as cited in study report): 1-ethenyl-2-pyrrolidinone (N-vinyl-2-pyrrolidinone; NVP)
- Analytical purity: no data
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 5 uCi 3H-NVP and 2.5 uCi 14C-NVP (3H:14C ratio = 2:1)
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- 3 seperate experiments reported:
- Urinary and Fecal Excretion
- Biliary Excretion
- Distribution
For excretion studies, animals were housed in metabolism cages for 6 days for collection of urine and feces
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- water
- Duration and frequency of treatment / exposure:
- Single treatment
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Urinary and Fecal Excretion: ca. 6 mg/kg
Biliary Excretion: ca 5.2 mg/kg
Distribution: ca. 4.4 mg/kg
- No. of animals per sex per dose / concentration:
- Urinary and Fecal Excretion: 4 rats
Biliary Excretion: 5 rats
Distribution: 3 rats - Control animals:
- no
- Details on dosing and sampling:
- Urinary and Fecal Excretion: Rats were coadministered intravenously single doses of 5 uCi 3H-NVP and 2.5 uCi 14C-NVP (3H:14C ratio = 2:1) at the jugular vein. The animals were anesthetized for application. Urine and feces were collected for 6 days and examined for 3H- and 14C-activity. In additino, the 6 and 12 hour urine samples were analyzed for intact radiolabelled NVP. Urine samples were further analyzed by radiomonitored HPLC to indentify metabolites.
Biliary Excretion: Rats were anesthetized and remained in anesthesia throughout the study. Jugular vein and bile duct were cannulated and each rat was given an i.v. dose of 5 uCi 3H-NVP and 2.5 uCi 14C-NVP (3H:14C ratio = 2:1). Bile samples were collected every 15 min for 2 hours, then every 30 min for another 4 hours. These samples were examined for total radioactivity as well as for intact radiolabelled NVP.
Metabolism: Rats were coadministered intravenously single doses of 5uCi 3H-NVP and 2.5 uCi 14C-NVP (3H:14C ratio = 2:1) at the jugular vein. The animals were anesthetized for application. Urine was collected after 6 hours and examined by high performance liquid chromatography (HPLC).
Distribution: Rats were anesthetized and remained in anesthesia until sacrifice. The jugular vein was cannulated and each rat was given an i.v. dose of 5 uCi 3H-NVP and 2.5 uCi 14C-NVP (3H:14C ratio = 2:1). Six hours later, the rats were sacrificed and the major organs were excised and analyzed for radioactivity.
Results and discussion
- Preliminary studies:
- The disposition and metabolism of 1-ethenyl-2-pyrrolidinone (N-vinyl-2-pyrrolidinone; NVP) was studied in a series of preliminary experiments in male Sprague-Dawley rats. Initially, three rats were anesthetized and remained in anesthesia until sacrifice. The jugular vein was cannulated and each rat was given an i.v. dose of 5 uCi 14C-NVP. Six hours later, the rats were sacrificed and the major organs were excised and analyzed for radioactivity. Blood samples (0.4 ml) were withdrawn 10, 20, 30, 45, 60, 120, 240 and 360 minutes after application. In another experiment, nine rats were treated as described above and three rats each were sacrificed 15, 30 and 90 min after dosing for evaluation of 14C-activity in organs. The examination of the organs showed that the liver, kidneys and small intestine (including its contents) had the highest concentration of radioactivity. The lowest values were found in the spleen, adrenal glands, thymus, thyroid gland and brain. Blood levels of intact 14C-NVP decreased from 6.00 to 0.51% of the dose over the 6 hours period after application of 5uCi 14C-NVP. Blood levels followed a biphasic kinetic with a half-life or 1.9 hours.
In a follow-up experiment, four rats each were given a 5.0 uCi or 2.0 uCi i.v. dose of 14C-NVP; two rats each were given 2.86 uCi or 1.16 uCi. Urine, feces and expired carbon dioxide (only of the rats given 2.86 or 1.16 uCi) were collected for up to 6 days and analysed for total radioactivity. For biliary excretion studies, another four rats were anesthetized and remained in anesthesia throughout the study. Jugular vein and bile duct were cannulated and each rat was given an i.v. dose of 5 uCi 3H-NVP and 2.5 uCi 14C-NVP. Bile samples were collected every 15 min for 2 hours, then every 30 min for another 4 hours. These samples were examined for total radioactivity as well as for intact radiolabelled NVP. By 12 hours after application, 74.9% of the administered dose was determined in urine and 0.43% was found in feces. Rats given 2 uCi had excreted 85.8% in the urine and 1.06% in the feces. Intact 14C-NVP excreted to the urine within the first 12 hours after these two doses ranged from 0 to 0.585% in the 5 uCi-group and from 0 to 0.398% in the 2 uCi-group. Urinary and fecal excretion of 14C-activity was similar in the rats given 2.86 and 1.16 uCi. The cumulative radioactivity found in the expired carbon dioxide 48 hours after the 2.86 uCi dose and 54 hours after the 1.16 uCi dose was less than 3.5% of the administered dose. Six hours after i.v. administration of a 5.0 uCi dose, 18.7% of the 14C-activity was determined in the bile. Intact NVP excreted to the bile was found as 0.46% of the 14C-dose 6 hours after administration.
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- Urine: Within 12 hours after dosing, 67.7% of the administered amount of 3H-radioactivity and 68.8% of the administered dose of 14C-radioactivity was determined in urine.
- Type:
- excretion
- Results:
- Uriine: Inact NVP excreted in the urine was less than 0.31% of the total dose.
- Type:
- excretion
- Results:
- Urine: About 89% of either dose was excreted in urine by day 2 with very little excreted after day 6.
- Type:
- excretion
- Results:
- Feces: 0.22% of 3H-activity and 0.19% of 14C-activity was found after 12 hours. By day 6, around 5 to 8% was excreted in feces.
- Type:
- excretion
- Results:
- Biliary excretion of radioactivity: Six hours after i.v. administration, 24.9% of the 3H dose and 23.3% of the 14C dose was determined in the bile.
- Type:
- excretion
- Results:
- Biliary excretion of intact NVP: Intact NVP excreted to the bile was found as 0.88% of the 3H dose and 0.85% of the 14C dose 6 hours after adminstration.
- Type:
- metabolism
- Results:
- The two major matabolites could not be identified and accounted for ca. 50% of 14C radioactivity and ca. 33% of 3H radioactivity. Further details below.
- Type:
- distribution
- Results:
- The liver, kidneys and small intestine (including its contents) had the highest concentration of radioactivity for both radiolabels (about 5, 1 and 2.5% of the dose administered, respectively).
- Type:
- distribution
- Results:
- The lowest values were found in the spleen, adrenal glands, thymus, thyroid gland and brain (0.01 - 0.15% of the dose administered). The values for 3H- and 14C-radioactivity were similar.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Urine analysis by radiomonitored reversed phase HPLC showed two major peaks acounting 50 and 33% of both the 3H- and 14C-excreted activity, eluting at 14.0 and 52.5 min, respectively. Minor peaks were determined at an elution time of 30.5 min, containing 5% of each radiolabel and at an elution time of 27.5 min containing 11.7% of the 3H-activity and 5.6% of the 14C-activity. According to the authors, the peak eluting at 27.5 min might be attributed to an overlap between N-acetyl-gamma-amino butyric acid and 2-pyrrolidinone. The minor metabolite eluting at 30.5 min was believed to be N-vinyl succinimide. The major metabolite remained unidentified. No further data.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.